Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma
Status:
Unknown status
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This prospective, non-randomized phase II study aims to compare radiotherapy and concurrent
nimotuzumab with concurrent chemoradiotherapy to obtain a non-inferior pCR rate and
pathological lymph node metastases rate in premise of lower toxicities in locally advanced
esophageal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborators:
Affiliated Hospital of Hebei University Beijing Army General Hospital Beijing Hospital Fujian Cancer Hospital Hebei Medical University Fourth Hospital Henan Cancer Hospital Peking University First Hospital The Affiliated Hospital of Inner Mongolia Medical University The First Affiliated Hospital with Nanjing Medical University Tianjin Medical University Cancer Institute and Hospital